The Food and Drug Administration (FDA) has approved Ascor (ascorbic acid injection; McGuff Pharmaceuticals) for the short-term (up to 1 week) treatment of scurvy in adult and pediatric patients ages 5 months and older for whom oral administration is not possible, insufficient, or contraindicated.
While the exact mechanism of action of ascorbic acid in the treatment of scurvy is unknown, administration is believed to restore the body pool of ascorbic acid.
Acute and chronic oxalate nephropathy have been reported with prolonged administration of high doses of ascorbic acid; the maximum recommended duration of Ascor administration is 1 week. If there is no improvement in scorbutic symptoms after 1 week, patients may be retreated until resolution of symptoms is observed.
In addition, hemolysis has been reported with administration of ascorbic acid in patients with glucose-6-phosphate dehydrogenase deficiency.
Ascor is supplied in a 50mL pharmacy bulk package of sterile, preservative-free, pyrogen-free ascorbic acid (500mg/mL) in a solution containing edetate disodium (0.025%), water for injection and sodium bicarbonate for pH adjustment. The pharmacy bulk package is intended for dispensing of single doses to multiple patients in a pharmacy admixture program.
For more information visit McGuffPharmaceuticals.com.